Participant Characteristics by Vaccination and SARS-CoV-2 Status at Enrollment (n = 542)
| . | Inpatient Participants (n = 542) . | |||||
|---|---|---|---|---|---|---|
| . | Vaccinated SARS-CoV-2 Positive (n = 140)a . | Unvaccinated SARS-CoV-2 Positive (n = 152) . | SARS-CoV-2 Negative (n = 250) . | |||
| Age, % (n) | ||||||
| <30 y | 0.0 | (0) | 0.7 | (1) | 1.6 | (4) |
| ≥30 and <40 y | 3.6 | (5) | 9.9 | (15) | 5.6 | (14) |
| ≥40 and <50 y | 1.4 | (2) | 12.5 | (19) | 8.0 | (20) |
| ≥50 and <60 y | 12.9 | (18) | 23.7 | (36) | 16.0 | (40) |
| ≥60 and <70 y | 25.0 | (35) | 25.0 | (38) | 31.2 | (78) |
| ≥70 and <80 y | 45.7 | (64) | 21.7 | (33) | 26.4 | (66) |
| ≥80 y | 11.4 | (16) | 6.6 | (10) | 11.2 | (28) |
| Sex, % (n) | ||||||
| Female | 3.6 | (5) | 14.5 | (22) | 4.8 | (12) |
| Male | 96.4 | (135) | 85.5 | (130) | 95.2 | (238) |
| Unknown | 0.0 | (0) | 0.0 | (0) | 0.0 | (0) |
| Race, % (n) | ||||||
| White | 56.4 | (75) | 63.8 | (95) | 51.0 | (122) |
| Black or African American | 40.6 | (54) | 30.2 | (45) | 43.1 | (103) |
| Pacific Islander, Asian, or American Indian or Alaska Native | 0.8 | (1) | 1.3 | (2) | 2.1 | (5) |
| Other or multiple | 2.3 | (3) | 4.7 | (7) | 3.8 | (9) |
| Ethnicity, % (n) | ||||||
| Not Spanish, Hispanic, or Latino | 92.1 | (129) | 94.7 | (144) | 91.6 | (229) |
| Spanish, Hispanic, or Latino | 6.4 | (9) | 3.9 | (6) | 6.8 | (17) |
| Unknown | 1.4 | (2) | 1.3 | (2) | 1.6 | (4) |
| Charlson index, % (n) | ||||||
| 0 | 6.4 | (9) | 34.2 | (52) | 15.2 | (38) |
| 1–2 | 21.4 | (30) | 29.6 | (45) | 29.2 | (73) |
| 3–4 | 28.6 | (40) | 17.1 | (26) | 25.2 | (63) |
| 5+ | 43.6 | (61) | 19.1 | (29) | 30.4 | (76) |
| Calendar period, % (n) | ||||||
| Feb 2021–June 2021 | 5.0 | (7) | 42.1 | (64) | 21.2 | (53) |
| May 2021–Nov 2021 | 40.0 | (56) | 42.8 | (65) | 18.0 | (45) |
| After Nov 2021 | 55.0 | (77) | 15.1 | (23) | 60.8 | (152) |
| . | Inpatient Participants (n = 542) . | |||||
|---|---|---|---|---|---|---|
| . | Vaccinated SARS-CoV-2 Positive (n = 140)a . | Unvaccinated SARS-CoV-2 Positive (n = 152) . | SARS-CoV-2 Negative (n = 250) . | |||
| Age, % (n) | ||||||
| <30 y | 0.0 | (0) | 0.7 | (1) | 1.6 | (4) |
| ≥30 and <40 y | 3.6 | (5) | 9.9 | (15) | 5.6 | (14) |
| ≥40 and <50 y | 1.4 | (2) | 12.5 | (19) | 8.0 | (20) |
| ≥50 and <60 y | 12.9 | (18) | 23.7 | (36) | 16.0 | (40) |
| ≥60 and <70 y | 25.0 | (35) | 25.0 | (38) | 31.2 | (78) |
| ≥70 and <80 y | 45.7 | (64) | 21.7 | (33) | 26.4 | (66) |
| ≥80 y | 11.4 | (16) | 6.6 | (10) | 11.2 | (28) |
| Sex, % (n) | ||||||
| Female | 3.6 | (5) | 14.5 | (22) | 4.8 | (12) |
| Male | 96.4 | (135) | 85.5 | (130) | 95.2 | (238) |
| Unknown | 0.0 | (0) | 0.0 | (0) | 0.0 | (0) |
| Race, % (n) | ||||||
| White | 56.4 | (75) | 63.8 | (95) | 51.0 | (122) |
| Black or African American | 40.6 | (54) | 30.2 | (45) | 43.1 | (103) |
| Pacific Islander, Asian, or American Indian or Alaska Native | 0.8 | (1) | 1.3 | (2) | 2.1 | (5) |
| Other or multiple | 2.3 | (3) | 4.7 | (7) | 3.8 | (9) |
| Ethnicity, % (n) | ||||||
| Not Spanish, Hispanic, or Latino | 92.1 | (129) | 94.7 | (144) | 91.6 | (229) |
| Spanish, Hispanic, or Latino | 6.4 | (9) | 3.9 | (6) | 6.8 | (17) |
| Unknown | 1.4 | (2) | 1.3 | (2) | 1.6 | (4) |
| Charlson index, % (n) | ||||||
| 0 | 6.4 | (9) | 34.2 | (52) | 15.2 | (38) |
| 1–2 | 21.4 | (30) | 29.6 | (45) | 29.2 | (73) |
| 3–4 | 28.6 | (40) | 17.1 | (26) | 25.2 | (63) |
| 5+ | 43.6 | (61) | 19.1 | (29) | 30.4 | (76) |
| Calendar period, % (n) | ||||||
| Feb 2021–June 2021 | 5.0 | (7) | 42.1 | (64) | 21.2 | (53) |
| May 2021–Nov 2021 | 40.0 | (56) | 42.8 | (65) | 18.0 | (45) |
| After Nov 2021 | 55.0 | (77) | 15.1 | (23) | 60.8 | (152) |
Abbreviations: COVID-19, coronavirus disease 2019; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.
Vaccinated participants had completed a primary COVID-19 vaccine series (with or without a booster) ≥14 days before enrollment.
Participant Characteristics by Vaccination and SARS-CoV-2 Status at Enrollment (n = 542)
| . | Inpatient Participants (n = 542) . | |||||
|---|---|---|---|---|---|---|
| . | Vaccinated SARS-CoV-2 Positive (n = 140)a . | Unvaccinated SARS-CoV-2 Positive (n = 152) . | SARS-CoV-2 Negative (n = 250) . | |||
| Age, % (n) | ||||||
| <30 y | 0.0 | (0) | 0.7 | (1) | 1.6 | (4) |
| ≥30 and <40 y | 3.6 | (5) | 9.9 | (15) | 5.6 | (14) |
| ≥40 and <50 y | 1.4 | (2) | 12.5 | (19) | 8.0 | (20) |
| ≥50 and <60 y | 12.9 | (18) | 23.7 | (36) | 16.0 | (40) |
| ≥60 and <70 y | 25.0 | (35) | 25.0 | (38) | 31.2 | (78) |
| ≥70 and <80 y | 45.7 | (64) | 21.7 | (33) | 26.4 | (66) |
| ≥80 y | 11.4 | (16) | 6.6 | (10) | 11.2 | (28) |
| Sex, % (n) | ||||||
| Female | 3.6 | (5) | 14.5 | (22) | 4.8 | (12) |
| Male | 96.4 | (135) | 85.5 | (130) | 95.2 | (238) |
| Unknown | 0.0 | (0) | 0.0 | (0) | 0.0 | (0) |
| Race, % (n) | ||||||
| White | 56.4 | (75) | 63.8 | (95) | 51.0 | (122) |
| Black or African American | 40.6 | (54) | 30.2 | (45) | 43.1 | (103) |
| Pacific Islander, Asian, or American Indian or Alaska Native | 0.8 | (1) | 1.3 | (2) | 2.1 | (5) |
| Other or multiple | 2.3 | (3) | 4.7 | (7) | 3.8 | (9) |
| Ethnicity, % (n) | ||||||
| Not Spanish, Hispanic, or Latino | 92.1 | (129) | 94.7 | (144) | 91.6 | (229) |
| Spanish, Hispanic, or Latino | 6.4 | (9) | 3.9 | (6) | 6.8 | (17) |
| Unknown | 1.4 | (2) | 1.3 | (2) | 1.6 | (4) |
| Charlson index, % (n) | ||||||
| 0 | 6.4 | (9) | 34.2 | (52) | 15.2 | (38) |
| 1–2 | 21.4 | (30) | 29.6 | (45) | 29.2 | (73) |
| 3–4 | 28.6 | (40) | 17.1 | (26) | 25.2 | (63) |
| 5+ | 43.6 | (61) | 19.1 | (29) | 30.4 | (76) |
| Calendar period, % (n) | ||||||
| Feb 2021–June 2021 | 5.0 | (7) | 42.1 | (64) | 21.2 | (53) |
| May 2021–Nov 2021 | 40.0 | (56) | 42.8 | (65) | 18.0 | (45) |
| After Nov 2021 | 55.0 | (77) | 15.1 | (23) | 60.8 | (152) |
| . | Inpatient Participants (n = 542) . | |||||
|---|---|---|---|---|---|---|
| . | Vaccinated SARS-CoV-2 Positive (n = 140)a . | Unvaccinated SARS-CoV-2 Positive (n = 152) . | SARS-CoV-2 Negative (n = 250) . | |||
| Age, % (n) | ||||||
| <30 y | 0.0 | (0) | 0.7 | (1) | 1.6 | (4) |
| ≥30 and <40 y | 3.6 | (5) | 9.9 | (15) | 5.6 | (14) |
| ≥40 and <50 y | 1.4 | (2) | 12.5 | (19) | 8.0 | (20) |
| ≥50 and <60 y | 12.9 | (18) | 23.7 | (36) | 16.0 | (40) |
| ≥60 and <70 y | 25.0 | (35) | 25.0 | (38) | 31.2 | (78) |
| ≥70 and <80 y | 45.7 | (64) | 21.7 | (33) | 26.4 | (66) |
| ≥80 y | 11.4 | (16) | 6.6 | (10) | 11.2 | (28) |
| Sex, % (n) | ||||||
| Female | 3.6 | (5) | 14.5 | (22) | 4.8 | (12) |
| Male | 96.4 | (135) | 85.5 | (130) | 95.2 | (238) |
| Unknown | 0.0 | (0) | 0.0 | (0) | 0.0 | (0) |
| Race, % (n) | ||||||
| White | 56.4 | (75) | 63.8 | (95) | 51.0 | (122) |
| Black or African American | 40.6 | (54) | 30.2 | (45) | 43.1 | (103) |
| Pacific Islander, Asian, or American Indian or Alaska Native | 0.8 | (1) | 1.3 | (2) | 2.1 | (5) |
| Other or multiple | 2.3 | (3) | 4.7 | (7) | 3.8 | (9) |
| Ethnicity, % (n) | ||||||
| Not Spanish, Hispanic, or Latino | 92.1 | (129) | 94.7 | (144) | 91.6 | (229) |
| Spanish, Hispanic, or Latino | 6.4 | (9) | 3.9 | (6) | 6.8 | (17) |
| Unknown | 1.4 | (2) | 1.3 | (2) | 1.6 | (4) |
| Charlson index, % (n) | ||||||
| 0 | 6.4 | (9) | 34.2 | (52) | 15.2 | (38) |
| 1–2 | 21.4 | (30) | 29.6 | (45) | 29.2 | (73) |
| 3–4 | 28.6 | (40) | 17.1 | (26) | 25.2 | (63) |
| 5+ | 43.6 | (61) | 19.1 | (29) | 30.4 | (76) |
| Calendar period, % (n) | ||||||
| Feb 2021–June 2021 | 5.0 | (7) | 42.1 | (64) | 21.2 | (53) |
| May 2021–Nov 2021 | 40.0 | (56) | 42.8 | (65) | 18.0 | (45) |
| After Nov 2021 | 55.0 | (77) | 15.1 | (23) | 60.8 | (152) |
Abbreviations: COVID-19, coronavirus disease 2019; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.
Vaccinated participants had completed a primary COVID-19 vaccine series (with or without a booster) ≥14 days before enrollment.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
